Gilead’s TIGIT Program Perks Up After Lung Cancer Letdown
Oncology, HIV Offer R&D Catalysts In 2024
Executive Summary
The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.
You may also be interested in...
Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas
The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.
Gilead Sees Plenty Of Room For Yescarta Adoption To Grow
An exec told the company’s Q3 earnings call it was “surprising” that cell therapy adoption for LBCL remains around only 10% of eligible patients despite Yescarta producing strong clinical data.
As Gilead’s PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed
The ARC-7 trial showed a progression-free survival benefit in NSCLC, but the PFS benefit for zimberelimab/domvanalimab wasn’t as big as analysts and oncologists had hoped.